Literature DB >> 25168884

Pharmacokinetics, tissue distribution, and excretion of nomegestrol acetate in female rats.

Qingbiao Huang1, Xiaoke Chen2, Yan Zhu3, Lin Cao4, Jim E Riviere5.   

Abstract

Nomegestrol acetate (NOMAC), a synthetic progestogen derived from 19-norprogesterone, is an orally active drug with a strong affinity for the progesterone receptor. NOMAC inhibits ovulation and is devoid of undesirable androgenic and estrogenic activities. The aim of this study was to evaluate the pharmacokinetics, tissue distribution, and excretion of NOMAC in female rats. Sprague-Dawley female rats were orally administered a single dose of NOMAC (10, 20 or 40 mg/kg) and drug plasma concentrations at different times were determined by RP-HPLC. Tissue distribution at 1, 2, and 4 h and excretion of NOMAC into bile, urine, and feces after dosing were investigated. The results showed that NOMAC was rapidly absorbed after oral administration, with [Formula: see text] of 1-2 h. The plasma concentration-time curves were fitted in a two-compartment model. The exposure to NOMAC ([Formula: see text] and [Formula: see text]) increased dose proportionally from 10 to 40 mg/kg. The average CL and [Formula: see text] were 5.58 L/(h·kg) and 10.8 h, respectively. The highest concentrations of NOMAC in ovary, liver, kidney, lung, heart, brain, spleen, muscle, and uterus were observed at 2 h, whereas the highest concentrations in stomach, pituitary, and hypothalamus appeared at 1 h. The total cumulative excretion of NOMAC in feces (0-72 h), urine (0-72 h), and bile (0-48 h) was ~1.06, 0.03, and 0.08 % of the oral administered dose, respectively. This study indicated that NOMAC had a widespread distribution in tissues, including ovary, pituitary, and hypothalamus, which are main target tissues where NOMAC inhibits ovulation. NOMAC was excreted via both feces and urine with few unchanged NOMAC excreted. Enterohepatic circulation was found in the drug elimination; however, it did not significantly affect [Formula: see text].

Entities:  

Keywords:  Excretion; HPLC; NOMAC; Nomegestrol acetate; Pharmacokinetics; Tissue distribution

Mesh:

Substances:

Year:  2014        PMID: 25168884     DOI: 10.1007/s13318-014-0224-7

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  12 in total

1.  After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives.

Authors:  Joaquim Calaf I Alsina
Journal:  Eur J Contracept Reprod Health Care       Date:  2010-02       Impact factor: 1.848

Review 2.  The pharmacology of nomegestrol acetate.

Authors:  Xiangyan Ruan; Harald Seeger; Alfred O Mueck
Journal:  Maturitas       Date:  2012-02-24       Impact factor: 4.342

3.  Pharmacokinetic profile of nomegestrol acetate and 17β-estradiol after multiple and single dosing in healthy women.

Authors:  Mireille G F Gerrits; Peter G Schnabel; Teun M Post; Pierre A M Peeters
Journal:  Contraception       Date:  2012-08-13       Impact factor: 3.375

4.  The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women.

Authors:  B Couzinet; J Young; M Kujas; G Meduri; S Brailly; J L Thomas; P Chanson; G Schaison
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

5.  Enzyme immunoassay for nomegestrol acetate in human plasma.

Authors:  E Ezan; H Benech; R Bucourt; T Ardouin; C Tchernatinsky; J L Thomas; J Paris; J M Grognet
Journal:  J Steroid Biochem Mol Biol       Date:  1993-10       Impact factor: 4.292

Review 6.  An overview of nomegestrol acetate selective receptor binding and lack of estrogenic action on hormone-dependent cancer cells.

Authors:  J Shields-Botella; I Duc; E Duranti; F Puccio; P Bonnet; R Delansorne; J Paris
Journal:  J Steroid Biochem Mol Biol       Date:  2003-11       Impact factor: 4.292

7.  [Female contraception by a normal dose progestogen after 40 years of age. Possible association of nomegestrol--17-beta-estradiol acetate by percutaneous route].

Authors:  C Jamin
Journal:  Rev Fr Gynecol Obstet       Date:  1992-06

Review 8.  Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy.

Authors:  Stefano Lello
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

9.  Nomegestrol acetate/estradiol: in oral contraception.

Authors:  Lily P H Yang; Greg L Plosker
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

10.  Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary-ovarian function in women.

Authors:  B Bazin; R Thevenot; C Bursaux; J Paris
Journal:  Br J Obstet Gynaecol       Date:  1987-12
View more
  1 in total

1.  Nomegestrol Acetate Suppresses Human Endometrial Cancer RL95-2 Cells Proliferation In Vitro and In Vivo Possibly Related to Upregulating Expression of SUFU and Wnt7a.

Authors:  A-Ying Ma; Shu-Wu Xie; Jie-Yun Zhou; Yan Zhu
Journal:  Int J Mol Sci       Date:  2017-06-22       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.